BIOCYTOGEN PHARMA. H YC1 (I54) - Total Assets
Based on the latest financial reports, BIOCYTOGEN PHARMA. H YC1 (I54) holds total assets worth €3.72 Billion EUR (≈ $4.35 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore I54 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
BIOCYTOGEN PHARMA. H YC1 - Total Assets Trend (2021–2025)
This chart illustrates how BIOCYTOGEN PHARMA. H YC1's total assets have evolved over time, based on quarterly financial data. See shareholders equity of BIOCYTOGEN PHARMA. H YC1 for net asset value and shareholders' equity analysis.
BIOCYTOGEN PHARMA. H YC1 - Asset Composition Analysis
Current Asset Composition (December 2025)
BIOCYTOGEN PHARMA. H YC1's total assets of €3.72 Billion consist of 57.7% current assets and 42.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 42.0% |
| Accounts Receivable | €300.14 Million | 8.1% |
| Inventory | €174.75 Million | 4.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €13.36 Million | 0.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how BIOCYTOGEN PHARMA. H YC1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIOCYTOGEN PHARMA. H YC1 (I54) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIOCYTOGEN PHARMA. H YC1's current assets represent 57.7% of total assets in 2025, an increase from 38.0% in 2021.
- Cash Position: Cash and equivalents constituted 42.0% of total assets in 2025, up from 20.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 8.1% of total assets.
BIOCYTOGEN PHARMA. H YC1 Competitors by Total Assets
Key competitors of BIOCYTOGEN PHARMA. H YC1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Jinyu Bio-Technology Co Ltd
SHG:600201
|
China | CN¥6.54 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
BIOCYTOGEN PHARMA. H YC1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.31 | 1.53 | 1.34 |
| Quick Ratio | 2.12 | 1.33 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.22 Billion | €281.62 Million | €193.54 Million |
BIOCYTOGEN PHARMA. H YC1 - Advanced Valuation Insights
This section examines the relationship between BIOCYTOGEN PHARMA. H YC1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.92 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 54.2% |
| Total Assets | €3.72 Billion |
| Market Capitalization | $715.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values BIOCYTOGEN PHARMA. H YC1's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BIOCYTOGEN PHARMA. H YC1's assets grew by 54.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below shows the annual total assets of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €3.72 Billion ≈ $4.35 Billion |
+54.20% |
| 2024-12-31 | €2.42 Billion ≈ $2.82 Billion |
-1.39% |
| 2023-12-31 | €2.45 Billion ≈ $2.86 Billion |
-12.52% |
| 2022-12-31 | €2.80 Billion ≈ $3.27 Billion |
+21.58% |
| 2021-12-31 | €2.30 Billion ≈ $2.69 Billion |
-- |
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more